 | This is an archive of past discussions about Henri Termeer. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
Board of Directors
This is a list to track Termeer's tenure on various BODs.
The most recent biography, lists a number of companies where he is still active on the Board.[1]
"Henri A. Termeer, former CEO, Chairman and President of Genzyme Corporation. Mr. Termeer was appointed president of Genzyme in 1983 became its chief executive officer in 1985 and chairman in 1988. He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer is active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care. Mr. Termeer is a Board member of Massachusetts Institute of Technology Corporation and serves on its Executive Committee, a director of Massachusetts General Hospital, board member of Partners HealthCare, and a member of the Board of Fellows of Harvard Medical School. He sits on the boards of Biotechnology Industry Organization (BIO), Life Sciences Foundation, Boston Ballet, Museum of Science, Project Hope and WGBH. He also serves on the boards of Abiomed, Inc., AVEO Pharmaceuticals, Moderna Therapeutics, ProQR Therapeutics and Verastem, Inc.. Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden Business School at the University of Virginia."
— Orphan Drug Congress
Termeer and Gordon M. Binder[2][3] sit on the Boards of Directors of PhRMA and the Biotechnology Industry Organization.[2]
Termeer is on the board of Verastem
Genzyme(1983-2011)
Federal Reserve Bank of Boston
ABIOMED Inc
Massachusetts Institute of Technology Corporation
Massachusetts General Hospital
Partners HealthCare System[4][5]
Fellows of Harvard Medical School
Pharmaceutical Research and Manufacturers of America[4]
Moderna Therapeutics(2013-)
Termeer is "connected to 311 board members in 17 different organizations across 20 different industries"[6][7]: 296 including Verastem, Inc.[6][8] He has the legacy of being the "longest-serving CEO in the biotechnology industry.[9]
Termeeer is on the biotechnology start-up Cambridge-based Verastem's Board of Directors with CEO Christoph Westphal.[6][8]
Other affiliations
Termeer is "connected to 311 board members in 17 different organizations across 20 different industries."[6]
- AutoImmune Inc.
- Diacrin, Inc.
- rEVO Biologics, Inc.
- IBM Collaboration Solutions
- ABIOMED Europe GmbH
- GelTex Pharmaceuticals, Inc.
- ABIOMED, Inc.
- Allergan Inc.
- Genzyme Tissue Repair
- Genzyme Corporation
- Tekla Life Sciences Investors
- Tekla Healthcare Investors
- Genzyme Oncology, Inc.
- Genzyme Surgical Products
- Genzyme General
- Medical Simulation Corporation
- AVEO Pharmaceuticals, Inc.
- Partners HealthCare System, Inc.
- Federal Reserve Bank of Boston Inc.
- Biotechnology Industry Organization
- Erasmus University
- Capital Royalty L.P
- Federal Reserve Bank of Atlanta
- Colgate W. Darden Graduate School of Business Administration
- Longwood Founders Management, LLC
- Verastem, Inc.
- Moderna Therapeutics, Inc.
- ProQR Therapeutics
- Fellows of Harvard Medical School Termeer serves on their Board of Directors.[4][10]
- ^ Terrapinn Holdings Ltd (2015). Mr Henri Termeer: Chief Executive Officer, Former Genzyme. Retrieved 27 September 2015.
{{cite conference}}: Unknown parameter|Conference=ignored (|conference=suggested) (help) - ^ a b "Gordon M. Binder", Bloomberg Business Week, nd
- ^ "Biography", Milken Institute, nd
- ^ a b c Cite error: The named reference
Verastem_2015was invoked but never defined (see the help page). - ^ "Board of Directors", Partners HealthCare System
- ^ a b c d Verastem Inc (VSTM:NASDAQ GM), Bloomberg
- ^ "The institutional embeddedness of high-tech regions: relational foundations of the Boston biotechnology community". Clusters, networks, and innovation. Vol. 261. 2005.
{{cite book}}:|access-date=requires|url=(help); Unknown parameter|authors=ignored (help); Unknown parameter|editors=ignored (|editor=suggested) (help) - ^ a b Gavin Rynne, Mark Jones, ed. (2013), Conversations with Henri Termeer (PDF), The Life Sciences Foundation Oral History Program, San Francisco, retrieved 7 July 2015
{{citation}}: CS1 maint: location missing publisher (link) Oral history conducted by Ted Everson, Jennifer Dionisio, Pei Koay, and Arnold Thackray, May 23, December 7, 2006, August 2, 2007, December 18, 2008 & September 30, 2011 - ^ Cite error: The named reference
Bloomberg_Private_equity_2011was invoked but never defined (see the help page). - ^ "Board of Directors", Fellows of Harvard Medical School